Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Item 1.01 Entry into a Material Definitive Agreement

On February 12, 2014, OXiGENE, Inc., a Delaware corporation ("OXiGENE"), entered
into a Securities Purchase Agreement (the "Purchase Agreement") with certain
investors, pursuant to which OXiGENE agreed to sell, in a registered public
offering, an aggregate of approximately $12 million of units, at a price per
unit of $2.05. Each unit consists of one share of common stock and 0.5 of a
warrant to purchase a share of OXiGENE common stock. The warrants have an
exercise price of $2.75 per share, shall be exercisable immediately and will
expire five years from the date of issuance. The closing of the offering is
expected to occur on or about February 18, 2014, subject to satisfaction of
customary closing conditions set forth in the Purchase Agreement. The Purchase
Agreement also contains representations, warranties, indemnification and other
provisions customary for transactions of this nature.

OXiGENE entered into a letter agreement with H.C. Wainwright & Co., LLC (the
"Placement Agent"), dated February 11, 2014, pursuant to which the Placement
Agent agreed to serve as the agent for OXiGENE in connection with the Offering.
OXiGENE agreed to pay the Placement Agent a cash placement fee equal to 7% of
the aggregate purchase price for the securities sold in the Offering, plus a
non-accountable expense allowance equal to 1% of the gross proceeds of all
securities sold in the Offering, not to exceed $50,000. The Placement Agent will
also receive warrants equal to 5% of the aggregate number of shares sold in the
Offering, at an exercise price of $2.56 per share.

The foregoing descriptions of the Purchase Agreement, the warrants, and the
letter agreement with the Placement Agent are subject to, and qualified in their
entirety by, such documents attached hereto as Exhibits 10.1, 4.1, 4.2 and 1.1,
respectively, which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number Description
1.1 Letter agreement dated as of February 11, 2014, by and between
OXiGENE, Inc. and H.C. Wainwright & Co., LLC.
4.1 Form of Common Stock Purchase Warrant.
4.2 Form of Placement Agent Purchase Warrant.
10.1 Form of Securities Purchase Agreement dated as of February 12, 2014,
by and among OXiGENE, Inc. and the purchasers signatory thereto.